By modulating astrocytic mGluR5 activity, novel strategies may emerge to restore synaptic balance, reduce neuroinflammation, and offer innovative treatments for conditions like AD, depression, and SCZ [11, 71]. This evidence concerns the gene GRM5 and depressive disorder.